舒尼替尼治疗肾细胞癌致不良反应报告分析  

Analysis of ADR Induced by Sunitinib during Renal Cell Carcinoma Treatment

作　　者：王之舟[1] 闫素英[1] 曾红[1] 曾艳[1] 

机构地区：[1]首都医科大学宣武医院药剂科,北京100053

出　　处：《中国药房》2015年第5期644-647,共4页China Pharmacy

摘　　要：目的:探讨应用舒尼替尼治疗肾细胞癌(RCC)时引发不良反应(ADR)的特点及规律,为临床合理用药提供参考。方法:对北京市ADR监测中心2009年1月-2012年8月收集到的北京地区医院抗肿瘤药ADR报告中筛选出使用舒尼替尼治疗RCC的ADR报告128例,按患者性别、年龄、ADR程度、ADR累及器官/系统及临床表现、转归情况等进行分类,并作统计学分析。结果:40岁以上男性患者是发生ADR的主要人群(85例);最常见的ADR是引发手足综合征等皮肤及其附件损害(44例),其次为胃肠道系统损害(41例)和血液系统损害(40例);最严重的ADR是肝肾和呼吸系统的衰竭所致的死亡,共24例。结论:临床应正确认识舒尼替尼治疗肾细胞癌引发的ADR,对易于出现ADR的主要患者群进行重点监测,加强对ADR的宣传教育工作,保障患者的用药安全。OBJECTIVE： To investigate the characteristics and regularity of ADR induced by sunitinib during renal cell carcinoma （RCC） treatment, and to provide reference for rational drug use in the clinic. METHODS： 128 cases of sunitinib-induced ADR were collected from Beijing ADR Monitoring Center during Jan. 2009-Aug. 2012, and then classified and analyzed in respects of patient＇s age, gender, ADR degree, clinical manifestations, outcome, etc. RESULTS： Male patients aged 40 years old above were main group of ADR. Common ADR included hand-foot syndrome （44 cases）, gastrointestinal system discomfort （41 cases） and blood system lesion （40 cases）. Most severe ADR were death due to liver and kidney failure and respiratory system failure （24 cases）. CONCLUSIONS： It is necessary to understand ADR correctly, monitor patient group who is easily to suffer from ADR and strengthen ADR education to ensure the safety of drug use.

关 键 词：舒尼替尼 肾细胞癌 不良反应 分析 合理用药 

分 类 号：R969.3[医药卫生—药理学] R979.19[医药卫生—药学]